Vaderis raises $152.0M Series B (Switzerland, Aug 2026)
Reach the investors backing rounds like this
Backed by Life Sciences at Goldman Sachs Alternatives, TCGX +6 more · verified emails and LinkedIn on Datapile
Vaderis bags $152m Series B - BioXconomy
Vaderis is a biotechnology company focused on developing treatments for rare diseases, specifically hereditary hemorrhagic telangiectasia (HHT). The company has recently closed a $152 million Series B financing round to support the advancement of its investigational therapy, engasertib, which targets the underlying causes of HHT. This funding will enable Vaderis to conduct a Phase III clinical trial for this promising treatment option.
Vaderis bags $152m Series B BioXconomy
| Sep 18, 2026 | Piomic | $25.0M | Growth | Switzerland |
| Sep 18, 2026 | Aseptuva | $2.4M | Seed | Switzerland |
| Sep 14, 2026 | Aware Health | $12.0M | Seed | Switzerland |
| Sep 01, 2026 | xorlab | $5.3M | Series A+ | Switzerland |
11,960 investors back startups in Switzerland
You just read who funded Vaderis. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.